Zacks Investment Research
Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
Caris Life Sciences (CAI) is expected to report a 62.5% year-over-year decline in earnings for Q3 2026 despite 15.7% revenue growth. With a negative Earnings ESP of -45.46% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in the last four quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.